NORTHWEST BIOTHERAPEUTICS INCNWBO

時価総額

$3.5億

PER

がん向け免疫療法の新興企業。DCVaxプラットフォームと個別化ワクチンのDCVax‑Lを展開。2020年8月のFlaskworks買収と2023年12月の英国MHRAへのMAA提出。米国・英国・欧州で展開。

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-33	-67	-66	-136	-115	-80	-73	-36	-20	-530	179	-105	-63	-84
Depreciation and amortization	2	2	2	0	0	0	0	1	0	0	0	1	2	2
Amortization of debt discount	-	-	-	-	-	-	-	7	1	3	2	3	2	2
Change in fair value of derivatives	-	-	3	-15	16	18	-3	18	12	-435	239	-26	4	0
Change in fair value of share payable	-	-	-	-	-	-	-	-	-	-	-	0	-0	0
Change in fair value of convertible notes	-	-	-	-	-	-	-	-	-	-	-	-	-2	8
Convertible notes payable	-	-	-	-	-	-	-	-	-1	-	-	-	-	-
Loss from extinguishment of debt	-	-	-	-	-	-1	-13	0	-2	-2	-0	-3	-5	-14
Loss from issuance of debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-1
Operating Lease ROA	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Stock-based compensation for services	-	-	-	-	-	-	-	14	2	52	15	12	4	3
Warrant modifications associated with convertible notes under fair value option	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Loss from warrant modifications	-	-	-	-	-	-	-	-	-	-	-	-	-	-1
Non-cash financing cost	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Subtotal of non-cash charges	-	-	-	-	-	5	29	0	-7	498	-220	45	13	17
Prepaid expenses and other current assets	-	0	0	0	0	-0	0	0	1	2	-3	0	-1	-0
Other non-current assets	-	0	0	-	0	-0	-0	1	0	0	0	-1	0	0
Accounts payable and accrued expenses	7	8	8	5	4	1	1	-0	0	2	0	3	0	9
Related party accounts payable and accrued expenses	13	28	42	19	3	18	8	4	-4	0	-1	3	-4	1
Lease liabilities	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net cash used in operating activities	-15	-23	-38	-55	-79	-	-36	-35	-32	-32	-38	-53	-54	-57
Purchase of equipment and construction in progress	-	-	-	-	-	-	-	-	0	7	6	3	3	1
Net cash used in investing activities	-0	-0	0	-36	-7	-	0	45	-0	-8	-6	-3	-3	-1
Proceeds from issuance of Series C convertible preferred stock	-	-	-	-	-	-	-	-	-	-	-	19	13	8
Proceeds from Issuance of Common Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	14
Proceeds from Warrant Exercises	-	-	-	5	7	8	3	3	2	14	20	11	2	2
Proceeds from investor advance	-	-	-	-	-	-	-	-	-	-	-0	-3	-	-0
Proceeds from Notes Payable	8	8	8	-	-	5	10	8	7	9	30	6	20	14
Proceeds from Issuance of Convertible Notes Payable	-	-	-	-	-	-	-	-	-	-	-	-	13	20
Proceeds from contingent payment obligation	-	-	-	-	-	-	-	-	-	-	-	-	5	0
Repayment of notes payable	0	0	0	-	-	-	-	2	0	2	6	5	0	0
Repayment of convertible notes payable	1	3	4	-	-	-	3	5	-	0	-	-	-	1
Repayment of investor advances	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Net cash provided by financing activities	119	150	199	86	94	-	34	8	10	53	48	42	53	57
Effect of Exchange Rate on Cash and Cash Equivalents	-	-	-	-	-	-	-	-	-	-	-	6	-1	1
Net increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-7	-	-22	10	5	-8	-5	0
Convertible notes payable	-	-	-	-	-	-	0	1	1	0	-	-	0	0
Interest payments on notes payable	-	-	-	-	-	-	0	0	-	-	-	-	-	-
Cashless warrants and stock options exercise	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Reclassification of warrant liabilities to stockholders' deficit	-	-	-	-	-	-	-	-	-	-	-	-	76	-
Reclassification Of Equity Classified Warrants To Liability	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Issuance of common stock for conversion of debt and accrued interest	-	-	-	-	-	-	-	6	7	8	7	12	25	19
Debt Conversion, Converted Instrument, Amount	-	-	-	-	-	-	-	500,000	-	-	-	-	-	-
Conversion of Stock, Amount Converted	-	-	-	-	-	-	-	-	-	-	-	-	19	14
Capital expenditures included in accounts payable	-	-	-	-	-	-	-	-	-	1	0	1	0	0
Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption	-	-	-	-	-	-	-	-	-	-	-	3	1	-
Deemed dividend related to warrant modifications	-	-	-	-	-	-	-	-	-	-	-	-	2	1
Debt discount related to warrant modifications	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Offering cost related to warrant modification associated with a security purchase agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Reclassification between contingent payment obligation and convertible notes payable at fair value	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Reclassification of investor advances to convertible notes payable	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Reclassification Of Investor Advances To Stockholders Deficit	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Reclass earned but unissued milestone shares from equity to liability	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Right-of-use asset recognized in exchange for lease liability	-	-	-	-	-	-	-	-	-	-	-	-	-	0